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Background
VRC01 and a number of other broad and potently neu-
tralizing CD4 binding site antibodies have been isolated
from HIV positive individuals. These antibodies utilize
VH1-2 and make the majority of their contacts via the
framework portion of the heavy chain. Recently, it has
been noted that the germline precursors to these VRC01-
like antibodies do not bind to HIV Env nor does Env sti-
mulate B cell lines expressing these germline precursors.
This lack of interaction between germline antibodies and
Env may represent a significant block for re-elicitation of
these antibodies.
Methods
We engineered a modified Env to have affinity for the
VH1-2 germline antibodies. We believe this antigen will
selectively activate B cells that have the potential to eli-
cit VRC01-like antibodies.
Homology modeling and computational protein inter-
face design was used to predict mutations to modify
GP120 to have affinity for the VH1-2 germline antibodies.
Mutations identified during the computational design
were used to generate directed libraries that were screened
on the surface of yeast to optimize binding against the
germline predicted precursors of several VRC01-like anti-
bodies as well as their mature counterparts.
Results
Using the strategy outlined above, we have modified a
GP120 outer domain to have sub-micromolar affinity for
several VH1-2 germline antibodies while maintaining high
affinity for the VRC01-like matured antibodies. We have
shown in a cell-based assay that, when multimerized, the
engineered immunogen stimulates B-cell lines expressing
germline VRC01 and other VH1-2 germline antibodies.
Conclusion
Our immunogen offers a novel approach to re-elicit
VRC01-like antibodies. We have demonstrated proof of
principle that immunogens can be rationally directed to
target specific germline B cell receptors. If this approach
proves successful, it could become a generally applicable
strategy to selectively activate desirable antibodies when
creating new vaccines.
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